The Utility of Monitoring Potassium in Transgender, Gender Diverse, and Nonbinary Individuals on Spironolactone

    September 2022 in “ Journal of the Endocrine Society ”
    Hailey Hayes, Rachel Russell, Amber L. Haugen, Sneha Nagavally, Jenna Sarvaideo
    TLDR Young transgender, gender diverse, and nonbinary people on spironolactone have a low risk of high potassium, so frequent monitoring may not be needed.
    The study indicated that the incidence of hyperkalemia in transgender, gender diverse, and nonbinary (TGDNB) individuals taking spironolactone was low, especially in those aged 45 years or younger. However, the risk of hyperkalemia increased with age. These findings suggested that practice guidelines might have needed adjustment to reduce unnecessary potassium monitoring in TGDNB individuals aged 45 or younger who did not have comorbidities affecting potassium handling.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results